Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
Journal of Endocrinology · 2024
DOI: 10.1530/joe-23-0339 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, 2024. Verfasst von Ryan A Lafferty und 3 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Centre, Schools of Biomedical Sciences and Pharmacy & Pharmaceutical Sciences, Ulster University, Coleraine, Northern Ireland, UK. Hauptthemen laut MEDLINE: Receptors, Gastrointestinal Hormone, Obesity, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Recent approval of the dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, tirzepatide, for the management of type 2 diabetes mellitus (T2DM) has reinvigorated interest in exploitation of GIP receptor (GIPR) pathways as a means of metabolic disease management. However, debate has long surrounded the use of the GIPR as a therapeutic target and whether agonism or antagonism is of most benefit in management of obesity/diabetes. This controversy appears to be partly resolved by the success of tirzepatide. However, emerging studies indicate that prolonged GIPR agonism may desensitise the GIPR to essentially induce receptor antagonism, with this phenomenon suggested to be more pronounced in the human than rodent setting. Thus, deliberation continues to rage in relation to benefits of GIPR agonism vs antagonism. That said, as with GIPR agonism, it is clear that the metabolic advantages of sustained GIPR antagonism in obesity and obesity-driven forms of diabetes can be enhanced by concurrent GLP-1 receptor (GLP-1R) activation. This narrative review discusses various approaches of pharmacological GIPR antagonism including small molecule, peptide, monoclonal antibody and peptide-antibody conjugates, indicating stage of development and significance to the field. Taken together, there is little doubt that interesting times lie ahead for GIPR agonism and antagonism, either alone or when combined with GLP-1R agonists, as a therapeutic intervention for the management of obesity and associated metabolic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Research Centre, Schools of Biomedical Sciences and Pharmacy & Pharmaceutical Sciences, Ulster University, Coleraine, Northern Ireland, UK.
ORCID-Profile: Ryan A Lafferty, Nigel Irwin
Zitieren
APA
Lafferty, R. A., Flatt, P. R., Gault, V. A., & Irwin, N. (2024). Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?. Journal of Endocrinology. https://doi.org/10.1530/joe-23-0339
Vancouver
Lafferty RA, Flatt PR, Gault VA, Irwin N. Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?. Journal of Endocrinology. 2024. doi:10.1530/joe-23-0339
BibTeX
@article{Lafferty2024,
author = {Lafferty, Ryan A and Flatt, Peter R and Gault, Victor A and Irwin, Nigel},
title = {Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?},
journal = {Journal of Endocrinology},
year = {2024},
doi = {10.1530/joe-23-0339}
}
EUVIMED